FLAG Therapeutics’ two novel classes of investigational drugs, Anti-angiogenic & Anti-tubulin (AA/AT) and Purine Synthesis Inhibitors (PSI), are designed to harness the power of multiple therapeutic actions targeted by highly water-soluble small molecule compounds.
Engineered to specifically overcome the shortcomings of conventional cancer therapies, namely efficacy, tolerability and drug resistance issues, FLAG’s investigational compounds hold the potential to treat multiple cancer types, including brain, lung, ovarian and pancreatic.
To date, more than $25 million in non-dilutive funding has been used to synthesize, optimize and screen compounds in vitro and in vivo, resulting in a library of thousands of promising compounds. The mechanisms of action for both classes of compounds have been fully elucidated and validated, thereby potentially minimizing development risks and facilitating clinical development.
FLAG's compounds have undergone:
Structural Activity Relationship (SAR) Analysis
In vitro activity screening (NCI 60 cell line panel)
Mechanism of action elucidation
In vivo efficacy studies with clinically relevant comparator